Skip to content

AKBA - Akebia Therapeutics, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchA

Akebia Ther

AKBA · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

A

AKBAAkebia Ther

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $3.32
52-wk low: $0.81
Prev close: $2.08
Mkt cap: $245.3M
Fwd P/E: 28.7x
Beta: 0.23

Smart money

8 funds hold a position.

Real smart money

Funds holding this stock

8 holders

Combined position$51.9M

AQ
AQR
Q2 2026 13F
$10.4M
position
MI
Millennium
Israel Englander · Q2 2026 13F

Earnings

Reported Aug 5, 2026

Earnings came in $0.01 a share above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -13.5%
Forward P/E: 28.74
Market cap: $245M

Valuation

P/S1.12
P/B9.49

Quality

Operating margin-5.5%

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: AKBA
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Market cap: $245.35M
Beta: 0.23

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/S

1.1x

P/B

9.5x

Profit margin

-13.5%

Op margin

-5.5%

ROE

-109.4%

$3.6M

position

TS

Two Sigma

Q2 2026 13F

$2.8M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for AKBA

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.02+$0.01

-$0.03 expected

Next report

What the street expects next

ROE

-109.4%

ROA-1.1%

Growth

Beta0.23